Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (863)	1/16/2000 12:18:00 AM
From: scaram(o)uche	Respond to of 4474

>> Are people even aware of the hidden gem that lies in that PNAS paper this fall? << Sure, some of us are. A friend, who posts under the handle of "Where'd He Go" just returned from the recent Keystone meeting. Before he left, I asked him to watch for ARIA reports regarding the bundled domains. You can write and ask him to verify. Or, you can question me and wait for any of the other 40 people who participate in a listserv that was spawned in the BVF thread...... Subject 19115 to come along and verify. If you're here to inform us of material stuff, great!..... we'll all welcome it, hypesters and non-hypesters alike. If you're here to question our knowledge, I'd say that it's not a particularly constructive bent. Your choice, however. Don't assume that something that is not posted is not known.

To: scott_jiminez who wrote (863)	1/16/2000 9:10:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 4474

1. If you want to call ARIA genomics or bioinformatics, fine with me. Allow me to disagree. End of discussion as far as I am concerned. 2. I presented a possible explanation or even account of why the stock has behaved the way it did. If that struck you as pretentious, so be it. I wonder why your explanation is not pretentious -g-. Again, fine with me. 3. Complexities of ARGENT. I am referring to clinical development. Again, if one wants to believe that developing this multi-component scheme is as "easy and straightforward" as any other old drug or even direct gene therapy, fine with me. Allow me to disagree. As for calling Schreiber or Crabtree, I am not sure what the point would be when I can read the papers, even had the luck of listening to Schreiber himself explain the whole thing in a Protein Society meeting a few years back. Good afternoon and good luck with your ARIA investment. I will continue to hold a portion of my shares bought at 1 1/16(sorry I could not hit the ~ 1/2 bottom, oh well), waiting for that big pharma deal and further clinical progress. PB (resident hair splitter, move over Dr. Harmon -g-)

To: scott_jiminez who wrote (863)	1/18/2000 5:49:00 AM
From: SnowShredder	Respond to of 4474

Hi Scott, Gelsinger's death was not just unfortunate; it was unnecessary. I agree that his death was very unfortunate, but I'm confused at why you think his death was unnecessary...as if they planned it? I'm not sure of Wilson's status at the moment but there are sure to be some serious repercussions at Penn. Some have spoken strongly that Ariad should actively seek another partner. I'm not so sure...since the ramifications of this tragedy will be felt in all GT centers. Wilson is still highly respected...BWDIK Best of Luck, Where'd He Go?